Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: An exploratory subgroup analysis

American Journal Geriatric Pharmacotherapy

Volumn 7, Issue 6, 2009, Pages 373-382

  Zinner, Norman ^a   Noe, Les ^b   Rasouliyan, Lawrence ^b   Marshall, Thomas ^c   Christopher Runken, M ^d   Seifeldin, Raafat ^c  

^a Western Clinical Research   (United States)

^b ICON CLINICAL RESEARCH   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

elderly; overactive bladder; quality of life; solifenacin; tolterodine; work productivity

Indexed keywords

SOLIFENACIN; TOLTERODINE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; EXPLORATORY RESEARCH; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PHYSICAL DISABILITY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION; URINARY URGENCY; WORK CAPACITY;

AGED; EFFICIENCY; FEMALE; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE;

EID: 74549161752     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2009.11.004     Document Type: Article

References (35)

1. Hu T.W., Wagner T.H., Bentkover J.D., et al. Estimated economic costs of overactive bladder in the United States. Urology. 61 (2003) 1123-1128
2. Hannestad Y.S., Rortveit G., Sandvik H., Hunskaar S., and Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. A community-based epidemiological survey of female urinary incontinence: The Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol. 53 (2000) 1150-1157
3. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 20 (2003) 327-336
4. Abrams P., Cardozo L., Fall M., et al., Standardization Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: Report from the standardisation subcommittee of the International Continence Society. Urology. 61 (2003) 37-49
5. Wagner T.H., Hu T.W., Bentkover J., et al. Health-related consequences of overactive bladder. Am J Manag Care. 8 Suppl 19 (2002) S598-S607
6. Brown J.S., McGhan W.F., and Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 6 Suppl 11 (2000) S574-S579
7. Voytas J. The role of geriatricians and family practitioners in the treatment of overactive bladder and incontinence. Rev Urol. 4 Suppl 4 (2002) S44-S49
8. Thom D.H., Haan M.N., and Van Den Eeden S.K. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 26 (1997) 367-374
9. Hu T.W., Moore K., Suback L., et al. Economics of incontinence. In: Abrams P., Koury S., and Wein A. (Eds). Incontinence (2002), Health Publication Limited, Plymouth, United Kingdom 965-983
10. Hu T.W., and Wagner T.H. Health-related consequences of overactive bladder: An economic perspective. BJU Int. 96 Suppl 1 (2005) 43-45
11. Abrams P., Kelleher C.J., Kerr L.A., and Rogers R.G. Overactive bladder significantly affects quality of life. Am J Manag Care. 6 Suppl 11 (2000) S580-S590
12. Burgio K.L. Influence of behavior modification on overactive bladder. Urology 60 Suppl 1 (2002) 72-76
13. Burgio K.L. Influence of behavior modification on overactive bladder. Urology 60 Suppl 1 (2002) 77
14. Chapple C., Khullar V., Gabriel Z., and Dooley J.A. The effects of antimuscarinic treatments in overactive bladder: A systematic review and meta-analysis [published correction appears in Eur Urol. 2005;48:875]. Eur Urol. 48 (2005) 5-26
15. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 Suppl 5A (2000) 33-46
16. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 Suppl 5A (2000) 50
17. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 172 (2004) 1919-1924
18. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al., STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol. 48 (2005) 464-470
19. Chapple C., Rechberger T., Al-Shukri S., et al., YM-905 Study Group. Randomized, double-blind placeboand tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 93 (2004) 303-310
20. Chapple C.R. Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. Expert Opin Pharmacother. 7 (2006) 2421-2434
21. Garely A.D., Kaufman J.M., Sand P.K., et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare Open-Label Trial (VOLT). Clin Ther. 28 (2006) 1935-1946
22. Kelleher C.J., Cardozo L., Chapple C.R., et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 95 (2005) 81-85
23. Chancellor M., Zinner N., Whitmore K., et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther. 30 (2008) 1766-1781
24. Zinner N., Noe L., Rasouliyan L., et al. Impact of solifenacin on resource utilization, work productivity, and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin. 24 (2008) 1583-1591
25. Coyne K., Revicki D., Hunt T., et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res. 11 (2002) 563-574
26. Coyne K.S., Matza L.S., and Thompson C.L. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 14 (2005) 849-855
27. Coyne K.S., Matza L.S., Thompson C.L., et al. Determining the importance of change in the overactive bladder questionnaire. J Urol. 176 (2006) 627-632
28. Coyne K.S., Matza L.S., Thompson C.L., et al. Determining the importance of change in the overactive bladder questionnaire. J Urol. 176 (2006) 632
29. Reilly M.C., Zbrozek A.S., and Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmaco Economics 4 (1993) 353-365
30. Furlong W.J., Feeny D.H., Torrance G.W., and Barr R.D. The Health Utilities Index (HUI) system for assessing healthrelated quality of life in clinical studies. Ann Med. 33 (2001) 375-384
31. Mattiasson A., Masala A., Morton R., and Bolodeoku J. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: Results from a randomized study. BJU Int. (2009) doi:10.1111/j.1464-410X.2009.08910.X
32. Wagg A., Wyndaele J.J., and Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am J Geriatr Pharmacother. 4 (2006) 14-24
33. Haab F., Cardozo L., Chapple C., Ridder A.M., and Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 47 (2005) 376-384
34. Abrams P., Larsson G., Chapple C., and Wein A.J. Factors involved in the success of antimuscarinic treatment. BJU Int. 83 Suppl 2 (1999) 42-47
35. Meyhoff H.H., Gerstenberg T.C., and Nordling J. Placebo-the drug of choice in female motor urge incontinence?. Br J Urol. 55 (1983) 34-37